PPARA and type 2 diabetes mellitus: A long-term study of human patients with type 2 diabetes showed that treatment with the PPARα agonist fenofibrate significantly reduced albuminuria [44], which could be potentially related to megalin function in the kidney, including its function as an albumin receptor.